JOHN MARQUEZ: Open Payments
NPI 1023153723 · ENGLEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,572 in 110 payments from 16 companies in 2025. Trend: 2023 $3,410 · 2024 $2,499 · 2025 $2,572
Food & beverage: $2,572
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 25 | $891 |
| ViiV Healthcare Company | 19 | $561 |
| ABBVIE INC. | 27 | $423 |
| Otsuka America Pharmaceutical, Inc. | 11 | $145 |
| Lilly USA, LLC | 5 | $95 |
| Merck Sharp & Dohme LLC | 3 | $92 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| Aimmune Therapeutics, Inc. | 4 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $44 |
| PFIZER INC. | 2 | $42 |
Products named: VRAYLAR, DOVATO, REXULTI, APRETUDE, QULIPTA, CABENUVA, PIFELTRO, Biktarvy.
Industry payments across CO — which companies pay providers there.
